Onestream Inc(OS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

OS Onestream Inc

Not Yet Opened 12-20 16:00:00 EST

29.66

+0.04

+0.14%

盘后29.59

-0.07-0.24%

18:25 EST

High30.54	Low28.40	Vol2.88M
Open29.10	D1 Closing29.62	Amplitude7.22%
Mkt Cap4.96B	Tradable Cap939.49M	Total Shares167.28M
T/O85.41M	T/O Rate9.09%	Tradable Shares31.68M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"OS","market":"US","secType":"STK","nameCN":"Onestream Inc","latestPrice":29.66,"timestamp":1734728400000,"preClose":29.62,"halted":0,"volume":2877787,"hourTrading":{"tag":"盘后","latestPrice":29.59,"preClose":29.66,"latestTime":"18:25 EST","volume":130673,"amount":3875549.092,"timestamp":1734737138226},"delay":0,"floatShares":31675412,"shares":167275096,"eps":-1.135048,"marketStatus":"Not Yet Opened","change":0.04,"latestTime":"12-20 16:00:00 EST","open":29.1,"high":30.54,"low":28.4,"amount":85412372.82556,"amplitude":0.072248,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.135048,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1734944400000},"marketStatusCode":0,"adr":0,"listingDate":1721793600000,"exchange":"NASDAQ","adjPreClose":29.62,"preHourTrading":{"tag":"盘前","latestPrice":29.1,"preClose":29.62,"latestTime":"09:29 EST","volume":437,"amount":12720.79032,"timestamp":1734704999104},"postHourTrading":{"tag":"盘后","latestPrice":29.59,"preClose":29.66,"latestTime":"18:25 EST","volume":130673,"amount":3875549.092,"timestamp":1734737138226},"volumeRatio":2.1325007500917272,"impliedVol":0.6071,"impliedVolPercentile":0.7647},"requestUrl":"/m/hq/s/OS/tweets","defaultTab":"tweets","newsList":[{"id":"2492925448","title":"Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2492925448","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492925448?lang=en_us&edition=fundamental","pubTime":"2024-12-20 21:00","pubTimestamp":1734699600,"startTime":"0","endTime":"0","summary":"FOSTER CITY, Calif., Dec. 20, 2024  -- Apollomics Inc.  , a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, announced today the results from its Phase 3 bridging trial of uproleselan in China in patients with relapsed or refractory acute myeloid leukemia. The trial did not demonstrate favorable benefit for uproleselan.Apollomics Inc. is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. Apollomics’ lead program is vebreltinib , a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met al","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/xOM5.ZiIjA.7Cie2ADU2Dg--~B/aD00NDU7dz0xMTQ3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/8175562b970e85b12c31c920d77417ad","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/xOM5.ZiIjA.7Cie2ADU2Dg--~B/aD00NDU7dz0xMTQ3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/8175562b970e85b12c31c920d77417ad"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/apollomics-announces-top-line-results-130000934.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["APLM","OS","APLMW","BK4097"],"gpt_icon":0},{"id":"2492178993","title":"OneStream initiated with an Outperform at Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2492178993","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492178993?lang=en_us&edition=fundamental","pubTime":"2024-12-19 21:35","pubTimestamp":1734615316,"startTime":"0","endTime":"0","summary":"Wedbush initiated coverage of OneStream (OS) with an Outperform rating and $40 price target OneStream is an enterprise finance management platform ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/onestream-initiated-with-an-outperform-at-wedbush?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":"9e13f0da20f7d6eb19089356bd64c3a7","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/onestream-initiated-with-an-outperform-at-wedbush?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4097","OS"],"gpt_icon":0},{"id":"2492612645","title":"Wedbush Initiates Onestream at Outperform With $40 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2492612645","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492612645?lang=en_us&edition=fundamental","pubTime":"2024-12-19 19:51","pubTimestamp":1734609065,"startTime":"0","endTime":"0","summary":"Onestream (OS) has an average rating of buy and mean price target of $36.19, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and r","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":"9e13f0da20f7d6eb19089356bd64c3a7","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OS"],"gpt_icon":0},{"id":"2492996973","title":"Officina Stellare Signs EUR 2 Mln Contract With Argotec","url":"https://stock-news.laohu8.com/highlight/detail?id=2492996973","media":"T-Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492996973?lang=en_us&edition=fundamental","pubTime":"2024-12-18 01:37","pubTimestamp":1734457069,"startTime":"0","endTime":"0","summary":"Officina Stellare SpA :Signs €2 Million Contract With Argotec.New Contract Lasts 14 Months.Further Company Coverage: Os.Mi. (Gdansk Newsroom). ((Gdansk.Newsroom@Thomsonreuters.Com; +48587696600;)).","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.trkd.thomsonreuters.com","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OS","BK4097"],"gpt_icon":0},{"id":"2492959531","title":"Affimed Reports Positive Clinical Update on AFM24/Atezolizumab Combination Therapy in Non-Small Cell Lung Cancer (NSCLC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2492959531","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492959531?lang=en_us&edition=fundamental","pubTime":"2024-12-17 19:30","pubTimestamp":1734435000,"startTime":"0","endTime":"0","summary":"In 33 heavily pretreated NSCLC EGFR wild-type (EGFRwt) patients the combination of AFM24 and atezolizumab shows an overall response rate (ORR) of 21% (6 confirmed responses, 1 response awaiting confir","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/17/2998078/0/en/Affimed-Reports-Positive-Clinical-Update-on-AFM24-Atezolizumab-Combination-Therapy-in-Non-Small-Cell-Lung-Cancer-NSCLC.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AE","BK4195","BK4588","BK4213","CR","BK4138","BK4599","LU0053666078.USD","L","FAS","PR","ALT","BK4139","BK4107","BK4211","OS","BK4585","PPS","BK4161","PFS","BK4097","LU1878469433.USD","AST"],"gpt_icon":0},{"id":"2491277693","title":"BioAtla Presented Data Characterizing Mutated KRAS Genotype and Clinical Outcomes in Patients with Advanced NSCLC Treated with Mecbotamab Vedotin (Mec-V), a CAB-AXL-ADC, at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2491277693","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491277693?lang=en_us&edition=fundamental","pubTime":"2024-12-16 21:00","pubTimestamp":1734354000,"startTime":"0","endTime":"0","summary":"Improved median overall survival (OS) for Mec-V treated patients with treatment-refractory non-small cell lung cancer (NSCLC) expressing mutated KRAS (mKRAS) as compared to Mec-V treated patient with ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/16/2997463/0/en/BioAtla-Presented-Data-Characterizing-Mutated-KRAS-Genotype-and-Clinical-Outcomes-in-Patients-with-Advanced-NSCLC-Treated-with-Mecbotamab-Vedotin-Mec-V-a-CAB-AXL-ADC-at-the-IASLC-2.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B7SZL793.SGD","AXL","BAS","CR","BK4097","BK4231","BK4161","AEIS","BK4157","ADC","IE00B19Z4B17.USD","IE0031619046.USD","OS","BK4080","IE00B66KJ199.SGD","BK4139","BCAB","BK4124","CAB"],"gpt_icon":0},{"id":"2491660974","title":"Merck’s KEYTRUDA® (pembrolizumab) Approved in China in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy After Surgery as Adjuvant Treatment for Patients With Resectable Stage II, IIIA or IIIB NSCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2491660974","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491660974?lang=en_us&edition=fundamental","pubTime":"2024-12-16 19:45","pubTimestamp":1734349500,"startTime":"0","endTime":"0","summary":"This approval marks the fourth non-small cell lung cancer  indication and the first indication in earlier stages of NSCLC for KEYTRUDA in China. \"While there have been several advances in the treatment of metastatic lung cancer over the past decade, lung cancer continues to be the leading cause of cancer death in China,\" said Dr. Heather Wakelee, principal investigator for KEYNOTE-671, thoracic medical oncologist and professor of medicine at Stanford University and past president of the International Association for the Study of Lung Cancer . \"This approval represents an important moment for certain patients with resectable NSCLC in China, providing a new option that has been shown in the KEYNOTE-671 study to significantly improve overall survival in these patients.\". This milestone builds on the momentum for worldwide approvals for KEYTRUDA in the perioperative setting for certain patients with earlier stages of NSCLC, including the European Union and Japan.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/iNBE7NKOJEEiJDa13P.2KA--~B/aD0yMTc7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/18fb22972e5bd41c4a9830cf186549ba","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/iNBE7NKOJEEiJDa13P.2KA--~B/aD0yMTc7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/18fb22972e5bd41c4a9830cf186549ba"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/merck-keytruda-pembrolizumab-approved-china-114500959.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MRK","OS","IE0009355771.USD","LU0965509010.AUD","HCC","IE00BLSP4239.USD","BK4599","LU2361044949.HKD","AST","RCC","SG9999001176.USD","LU1934455863.HKD","CRC","BK4585","LU1941712264.USD","LU0203345920.USD","LU1057294990.SGD","CPS","BK4161","LU0070302665.USD","LU1061106388.HKD","LU0965509283.SGD","LU2361045086.USD","CRT","IE00B4R5TH58.HKD","LU1116320737.USD","LU2324357040.USD","BCG","BK4588","LU0861579265.USD","IE00BN8TJ469.HKD","LU1430594728.SGD","GRO","BK4007","LU2023250504.SGD","LU1066051498.USD","LU1291159041.SGD","SG9999002232.USD","ALT","LU0265550359.USD","BTC","SG9999014567.USD","DM","IE00BBT3K403.USD","SG9999015341.SGD","BK4546","SSI","SG9999015358.SGD","LU1974910355.USD","HSCT"],"gpt_icon":0},{"id":"2491350715","title":"ROHM’s PMICs for SoCs Adopted in Reference Designs for Telechips’ Next-Generation Cockpits","url":"https://stock-news.laohu8.com/highlight/detail?id=2491350715","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491350715?lang=en_us&edition=fundamental","pubTime":"2024-12-13 06:00","pubTimestamp":1734040800,"startTime":"0","endTime":"0","summary":"Shipments to European automakers scheduled to begin in 2025. ROHM PMICs to be used in Telechips' Reference Designs. Focus is on the next-generation cockpit SoCs Dolphin3 and Dolphin5. ROHM and Telechips have been engaged in technical exchanges since 2021, fostering a close collaborative relationship from the early stages of SoC chip design. As a first step in achieving this goal, ROHM’s power supply solutions have been integrated into Telechips’ power supply reference designs. These solutions support diverse model development by combining sub-PMICs and DrMOS with the main PMIC for SoCs.“Telechips offers reference designs and core technologies centered around automotive SoCs for next-generation ADAS and cockpit applications. We are pleased to have developed a power reference design that supports the advanced features and larger displays found in next-generation cockpits by utilizing power solutions from ROHM, a global semiconductor manufacturer. Leveraging ROHM’s power supply solutions ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/r_GNja0fCzN6bLPdksokvA--~B/aD00NTAwO3c9ODAwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/348f590dd6e44a2c54fa8ece80fd41e6","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/r_GNja0fCzN6bLPdksokvA--~B/aD00NTAwO3c9ODAwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/348f590dd6e44a2c54fa8ece80fd41e6"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/rohm-pmics-socs-adopted-reference-220000982.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2298322129.HKD","ROHCF","LU1978683503.SGD","LU0348723411.USD","BK4585","BK4512","ON","IE00BD6J9T35.USD","LU1854103824.USD","LU1861215975.USD","LU1861219969.SGD","BK4588","LU2357305700.SGD","LU1854104046.USD","LU1720051017.SGD","LU1548497426.USD","AP","ROHCY","OS","LU1861220033.SGD","BK4141","IE00BZ199S13.USD","LU2360107325.USD","BK4006","BK4097","LU1720051108.HKD","LU0724618433.USD","LU0124384867.USD","LU1861214812.USD"],"gpt_icon":0},{"id":"2490879633","title":"CEL-SCI Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration Head and Neck Cancer Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2490879633","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490879633?lang=en_us&edition=fundamental","pubTime":"2024-12-12 22:15","pubTimestamp":1734012900,"startTime":"0","endTime":"0","summary":"Multikine is the first cancer immunotherapy to show pre-surgical tumor regression in head and neck cancer in just 3 weeks - confirmed by pathology at surgery. Factors supporting the go-ahead for the 212-person registration study in the target population include:. Multikine led to significant rates of tumor regression. Pre-surgical tumor regressions were confirmed at surgery and forecast survival benefit. Target population is likely to show significant survival prolongation in the confirmatory study. Confirmatory study target population selection is based on:. Strong statistical significance in a large subgroup of 114 patients. Strong biological rationale for the results based on Multikine’s mechanism of action . The Phase 3 study missed the primary endpoint of 10% improvement in overall survival  in the ITT population  but showed a 46.5-month  OS benefit vs control  in the patients who received Multikine followed by surgery and radiotherapy. In the other group","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/8BmWiXx5HRLEXXBZF8uK2Q--~B/aD0yNDA7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/51c62ce853d0e3d5dff54cee0a1524f8","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/8BmWiXx5HRLEXXBZF8uK2Q--~B/aD0yNDA7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/51c62ce853d0e3d5dff54cee0a1524f8"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cel-sci-highlights-biological-rationale-141500652.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["OS","CEL","CVM","BK4097","BK4585","BK4161","LU0054578231.USD","ITT","LU0053671581.USD","BK4528","SAP","BK4588","BK4139","BK4023"],"gpt_icon":0},{"id":"2490338438","title":"Eli Lilly Reports Positive Data From Late-Stage Breast Cancer Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2490338438","media":"Zacks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490338438?lang=en_us&edition=fundamental","pubTime":"2024-12-12 21:39","pubTimestamp":1734010740,"startTime":"0","endTime":"0","summary":"Eli Lilly LLY announced results from the phase III EMBER-3 study, which showed that treatment with its orally administered investigational drug imlunestrant significantly reduced the risk of disease progression or death in certain patients with advanced breast cancer .The EMBER-3 study enrolled patients with estrogen receptor -positive, HER2-negative ABC whose disease progressed during or following an aromatase inhibitor  therapy, with or without a CDK 4/6 inhibitor. These patients were then randomized into three equal groups to receive imlunestrant monotherapy, a combination of imlunestrant and Lilly’s blockbuster breast cancer drug Verzenio  or standard of care  endocrine therapy .Treatment with imlunestrant monotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival  compared to SOC ET in patients with ESR1 mutations. Data from the study showed that the drug significantly reduced the risk of progress","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/qi8AmKRuXk4zL7mGsiR5yg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/qi8AmKRuXk4zL7mGsiR5yg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/eli-lilly-reports-positive-data-133900351.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4590","LU1804176565.USD","LU1868837300.USD","LU2237443382.USD","LU2237443895.HKD","LU2602419157.SGD","IE00BKVL7J92.USD","IE00BJJMRZ35.SGD","LU0097036916.USD","LU2360106947.USD","IE00BFTCPJ56.SGD","LU1983299246.USD","BK4532","LU0385154629.USD","LU1035775433.USD","PFS","SG9999018865.SGD","LU2264538146.SGD","LU0096364046.USD","SG9999014906.USD","EBC","SGXZ57979304.SGD","BK4211","LLY","LU1064131342.USD","NVO","BK4534","IE00BK4W5M84.HKD","LU0882574055.USD","BK4585","SG9999013999.USD","OS","LU0114720955.EUR","LU1057294990.SGD","LU2237443622.USD","IE00BK4W5L77.USD","LU1127390331.HKD","IE00B4R5TH58.HKD","ET","LU0109394709.USD","AZN","IE0009355771.USD","LU0109391861.USD","SSI","BK4097","SG9999001176.USD","LU2089984988.USD","LU2237438978.USD","LU2417539215.USD","LU1868836757.USD"],"gpt_icon":1},{"id":"2490467383","title":"Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2490467383","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490467383?lang=en_us&edition=fundamental","pubTime":"2024-12-12 21:15","pubTimestamp":1734009300,"startTime":"0","endTime":"0","summary":"Data shows strong overall survival, progression-free survival, and durability from novel combination of efti in combination with pembrolizumab in difficult-to-treat head and neck cancer patients with ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/12/2996174/0/en/Immutep-Reports-Promising-New-Data-in-Head-and-Neck-Cancer-at-ESMO-Immuno-Oncology-2024.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999001176.SGD","SG9999002232.USD","IE0002141913.USD","LU0058720904.USD","BK4563","LU1571399168.USD","LU1061106388.HKD","SG9999015358.SGD","IE00BJJMRZ35.SGD","BK4007","LU0965508806.USD","BK4533","IE000M9KFDE8.USD","LU2361044949.HKD","IMMP","PFS","LU0006306889.USD","SG9999014542.SGD","LU1037948897.HKD","SG9999014559.SGD","LU0211331839.USD","LU0208291251.USD","LU2106854487.HKD","BK4179","LU0965509101.SGD","OS","LU1430594728.SGD","IO","LU1989772840.SGD","LU0203345920.USD","SG9999014567.USD","LU0965509010.AUD","LU1934455277.USD","LU0122379950.USD","LU1291159041.SGD","PHH","IE00BLSP4239.USD","LU0985320562.USD","LU0234572021.USD","BK4097","WRD","BK4211","IE0009355771.USD","LU2361044865.SGD","LU2468319806.SGD","MRK","LU2112291526.USD","LU1989771016.USD","LU0203347892.USD","BK4588"],"gpt_icon":0},{"id":"2490823496","title":"HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2490823496","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490823496?lang=en_us&edition=fundamental","pubTime":"2024-12-12 12:00","pubTimestamp":1733976000,"startTime":"0","endTime":"0","summary":"HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Dec.  11, 2024  (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the Center for Drug Evaluation o","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/12/2995863/0/en/HUTCHMED-Announces-Breakthrough-Therapy-Designation-in-China-for-ORPATHYS-and-TAGRISSO-Combination-in-Certain-Lung-Cancer-Patients-After-Disease-Progression-on-EGFR-Inhibitor-Thera.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1587","BK4135","BK1191","BK4097","BK1588","00013","OS","CNS"],"gpt_icon":0},{"id":"2490894214","title":"AstraZeneca-Merck Partnered Lynparza Shows Long-Term Survival With Reduced Death Risk Of 28% In Breast Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2490894214","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490894214?lang=en_us&edition=fundamental","pubTime":"2024-12-12 03:10","pubTimestamp":1733944218,"startTime":"0","endTime":"0","summary":"AstraZeneca Plc  and Merck& Co Inc , on Wednesday, announced long-term results from the OlympiA Phase 3 trial.The trial showed Lynparza  demonstrated sustained, clinically meaningful improvements in overall survival , invasive disease-free survival , and distant disease-free survival  for people with germline BRCA-mutated  HER2-negative high-risk early breast cancer.Also Read: After Lung Cancer Approval, AstraZeneca’s Imfinzi Goes Under FDA Priority Review For Bladder Cancer. At a median follow-up of 6.1 years  in eligible patients, who had completed local treatment and standard neoadjuvant or adjuvant chemotherapy, Lynparza reduced the risk of death by 28% versus placebo.In addition,87.5% of patients treated withLynparza remained alive versus 83.2% of those on placebo.Lynparza reduced the risk of invasive breast cancer recurrence, second cancers, or death by 35% and reduced the risk of distant disease recurrence or death by 35% versus placebo.This article AstraZeneca-Merck Partnered L","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/GaL7aTAJNl9vj_IJCnqGiA--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/ea26a47393d00466b04b8a525b488c58","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/GaL7aTAJNl9vj_IJCnqGiA--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/ea26a47393d00466b04b8a525b488c58"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/astrazeneca-merck-partnered-lynparza-shows-191018685.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2324357040.USD","SGXZ57979304.SGD","SG9999014542.SGD","LU0122379950.USD","LU2089984988.USD","LU2023250843.SGD","LU0265550946.USD","IE00BBT3K403.USD","IE00BSNM7G36.USD","LU1934455277.USD","MRK","OS","LU1941712264.USD","LU0320765489.SGD","BK4533","LU1116320737.USD","LU0965509101.SGD","LU2468319806.SGD","LU1989771016.USD","IE00BN8TJ469.HKD","LU1989772840.SGD","LU1093756168.USD","IE000M9KFDE8.USD","SG9999013999.USD","SG9999014567.USD","BK4559","BK4550","LU1066051498.USD","IE00B1BXHZ80.USD","SG9999001440.SGD","SG9999015358.SGD","LU2361045086.USD","AZN","LU0289739699.SGD","IE00B4R5TH58.HKD","LU0861579265.USD","LU0070302665.USD","LU1057294990.SGD","BK4588","LU1061106388.HKD","LU1989772923.USD","BK4007","IE00B2B36J28.USD","LU2112291526.USD","LU2361044865.SGD","LU1116320901.HKD","BK4568","LU0985320562.USD","SG9999001176.USD","LU0006306889.USD"],"gpt_icon":0},{"id":"2490279860","title":"Eli Lilly's Investigational Cancer Drug Cuts Risk Of Death By 38% In Breast Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2490279860","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490279860?lang=en_us&edition=fundamental","pubTime":"2024-12-12 00:28","pubTimestamp":1733934514,"startTime":"0","endTime":"0","summary":"On Wednesday, Eli Lilly And Co  announced results from the Phase 3 EMBER-3 study of imlunestrant for estrogen receptor-positive (ER+), human epidermal growth factor receptor 2 negative advanced breast cancer, whose disease progressed on a prior aromatase inhibitor, with or without a CDK4/6 inhibitor.Imlunestrant demonstrated a statistically significant and clinically meaningful improvement in progression-free survival  as monotherapy in patients with an ESR1mutation versus standard of care endocrine therapy , reducing the risk of disease progression or death by 38%.Also Read: What’s Going On With Eli Lilly Stock On Tuesday?Imlunestrant in combination with Eli Lilly’s Verzenio  reduced the risk of progression or death by 43% versus imlunestrant alone, in all patients.The overall response rate  with imlunestrant was 14% compared to 8% with SOC ET in patients with anESR1 mutation.In all patients, the median PFS was 5.6 months with imlunestrant versus 5.5 months with standard-of-care endoc","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/ItiUVKqCfqVJHTVclnW6jQ--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/1958e8b1e60ed3cb3842f5579bc06c27","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/ItiUVKqCfqVJHTVclnW6jQ--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/1958e8b1e60ed3cb3842f5579bc06c27"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/eli-lillys-investigational-cancer-drug-162834130.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0198837287.USD","LU1127390331.HKD","LU0820561909.HKD","LU0109391861.USD","SG9999018865.SGD","LU1057294990.SGD","BK4211","LU2361045086.USD","IE00B1BXHZ80.USD","LU2237443895.HKD","LU1035775433.USD","LU2360106947.USD","SG9999014906.USD","LU0417517546.SGD","SG9999001176.SGD","LU0256863902.USD","SG9999017495.SGD","LLY","IE00BJT1NW94.SGD","LU1023059063.AUD","LU2089984988.USD","LU1868836757.USD","LU0820561818.USD","IE00BJJMRZ35.SGD","LU1988902786.USD","LU1974910355.USD","LU2112291526.USD","OS","LU0471298694.HKD","LU1093756325.SGD","BK4516","BK4533","LU1623119135.USD","LU1551013425.SGD","LU0708995401.HKD","LU1868836914.USD","LU0114720955.EUR","LU2237438978.USD","LU1712237335.SGD","LU1061106388.HKD","LU1093756168.USD","GB00BDT5M118.USD","IE00B4R5TH58.HKD","LU1917777945.USD","BK4007","LU1814569148.SGD","BK4534","IE00BK4W5M84.HKD","PFS","LU2265009873.SGD"],"gpt_icon":1},{"id":"2490866155","title":"LYNPARZA® (olaparib) demonstrated clinically meaningful prolonged survival benefit in early breast cancer in OlympiA Phase III trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2490866155","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490866155?lang=en_us&edition=fundamental","pubTime":"2024-12-11 23:15","pubTimestamp":1733930100,"startTime":"0","endTime":"0","summary":"First and only PARP inhibitor to improve survival in early breast cancer. WILMINGTON, Del., December 11, 2024----Updated results from the OlympiA Phase III trial showed AstraZeneca and Merck & Co., Inc’s, known as MSD outside of the US and Canada, LYNPARZA  demonstrated sustained, clinically meaningful improvements in overall survival , invasive disease-free survival  and distant disease-free survival  at six years for patients with germline BRCA-mutated  HER2-negative high-risk early breast cancer.Eliav Barr, Senior Vice President, Head of Global Clinical Development and C","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/ARG9pBkQU.InVGzB47YqBg--~B/aD00NzU7dz0xNDM4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/8ec7ccdd0c2fab1da78e61eea7bf33a6","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/ARG9pBkQU.InVGzB47YqBg--~B/aD00NzU7dz0xNDM4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/8ec7ccdd0c2fab1da78e61eea7bf33a6"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lynparza-olaparib-demonstrated-clinically-meaningful-151500770.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["HR","OS","BK4585","LU1917777945.USD","BK4114","III","BK4104","LU2456880835.USD","AZN","BK4134","BIG","LU1829250122.USD","LU2417539215.USD","BK4007","BK4097","BK4568","BK4588","LU2236285917.USD","LU2462157665.USD","LU2023250843.SGD","LU2023250504.SGD","BK4225","URI","LU1721428933.USD","NCI","BK4516","BK4202","LU2106854487.HKD","LU0889565916.HKD","LU1974910355.USD","BK4203","LU0109394709.USD","BK4220","LU0320765992.SGD"],"gpt_icon":0},{"id":"2490852528","title":"Goldman Sachs Initiates Onestream at Buy With $37 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2490852528","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490852528?lang=en_us&edition=fundamental","pubTime":"2024-12-11 21:34","pubTimestamp":1733924073,"startTime":"0","endTime":"0","summary":"Onestream (OS) has an average rating of buy and mean price target of $36.19, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and r","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OS"],"gpt_icon":0},{"id":"2490863633","title":"Lilly's Imlunestrant, an Oral SERD, Significantly Improved Progression-Free Survival as Monotherapy and in Combination with Verzenio® (abemaciclib) in Patients with ER+, HER2- Advanced Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2490863633","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490863633?lang=en_us&edition=fundamental","pubTime":"2024-12-11 21:15","pubTimestamp":1733922900,"startTime":"0","endTime":"0","summary":"As monotherapy, imlunestrant significantly reduced the risk of progression or death by 38% compared to standard endocrine therapy  in patients withESR1 mutations. These data were published simultaneously in the New England Journal of Medicine and will be presented today at the 2024 San Antonio Breast Cancer Symposium. In the EMBER-3 study, patients were randomized 1:1:1 to receive imlunestrant alone, SOC ET, or the imlunestrant-abemaciclib combination. Randomization was stratified by prior CDK4/6 inhibitor use, the presence of visceral metastases and geographic region. Patients enrolled as first line  treatment for ABC (32%), following disease recurrence on or within 12 months of completing adjuvant AI, with or without CDK4/6 inhibitor for early breast cancer , or as second line  treatment for ABC (64%), following progression on AI, with or without CDK4/6 inhibitor as initial therapy for ABC. Primary endpoints were investigator-assesse","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/lVAuq1Sjy2.E_X33eK_R8A--~B/aD0yMTk7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/lVAuq1Sjy2.E_X33eK_R8A--~B/aD0yMTk7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/lillys-imlunestrant-oral-serd-significantly-131500579.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lillys-imlunestrant-oral-serd-significantly-131500579.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SG9999018865.SGD","LU1878469433.USD","BK4007","SG9999001176.USD","LU1267930730.SGD","LU2461242641.AUD","IE00B1BXHZ80.USD","ALT","LU2264538146.SGD","OS","EBC","PFS","AEIS","LU1868836591.USD","BK4097","LU0354030511.USD","ET","IE00B2B36J28.USD","LU0106261372.USD","LU2237443465.HKD","CNS","BK4144","GRO","SG9999014898.SGD","LU0456855351.SGD","LU0320765059.SGD","IE00BFTCPJ56.SGD","LU0820561818.USD","LU2023250504.SGD","BK4157","LU1623119135.USD","BK4211","HR","LU2361045086.USD","BK4534","AST","LU1023059063.AUD","LU1366192091.USD","LU0203202063.USD","BK4561","SG9999018857.SGD","LU2361044949.HKD","IE00B7SZL793.SGD","LU0466842654.USD","SGXZ57979304.SGD","LU0820561909.HKD","LLY","BK4590","BK4195","IE00BJJMRZ35.SGD"],"gpt_icon":1},{"id":"2490212859","title":"BriaCell Presents Unprecedented Overall Survival Data in Metastatic Breast Cancer in Spotlight Poster at 2024 SABCS®","url":"https://stock-news.laohu8.com/highlight/detail?id=2490212859","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490212859?lang=en_us&edition=fundamental","pubTime":"2024-12-11 20:50","pubTimestamp":1733921400,"startTime":"0","endTime":"0","summary":"Median overall survival (OS) to date of 13.4 months for Phase 2 patients treated with the Phase 3 formulation (15.6 months for those treated since 2022), double that of comparable patients in the lite","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/11/2995320/0/en/BriaCell-Presents-Unprecedented-Overall-Survival-Data-in-Metastatic-Breast-Cancer-in-Spotlight-Poster-at-2024-SABCS.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OS","BK4097","NLR","BK4086","DTH","MBC","BK4135","CNS","CPI"],"gpt_icon":0},{"id":"2490855725","title":"Celcuity Presents Overall Survival Data from Phase 1b Study Evaluating Gedatolisib in Combination with Palbociclib and Endocrine Therapy at the 2024 San Antonio Breast Cancer Symposium","url":"https://stock-news.laohu8.com/highlight/detail?id=2490855725","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490855725?lang=en_us&edition=fundamental","pubTime":"2024-12-11 20:05","pubTimestamp":1733918700,"startTime":"0","endTime":"0","summary":"Median overall survival (OS) among patients with HR+, HER2- advanced breast cancer who were treatment-nave in the advanced setting was 77.3 months Median OS among patients previously treated with a CD","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/11/2995280/0/en/Celcuity-Presents-Overall-Survival-Data-from-Phase-1b-Study-Evaluating-Gedatolisib-in-Combination-with-Palbociclib-and-Endocrine-Therapy-at-the-2024-San-Antonio-Breast-Cancer-Sympo.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OS","BK4097"],"gpt_icon":0},{"id":"2490047849","title":"GSK's Blood Cancer Drug Shows Improved Survival Compared To Johnson & Johnson's Darzalex","url":"https://stock-news.laohu8.com/highlight/detail?id=2490047849","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490047849?lang=en_us&edition=fundamental","pubTime":"2024-12-11 02:14","pubTimestamp":1733854476,"startTime":"0","endTime":"0","summary":"On Monday, GSK plc  announced statistically significant and clinically meaningful overall survival  results from a planned interim analysis of the DREAMM-7 trial.The trial assessed Blenrep  in combination with bortezomib plus dexamethasone  versus Johnson & Johnson’s  Darzalex  in combination with bortezomib plus dexamethasone  as a second line or later treatment for relapsed or refractory multiple myeloma.These data were featured at the American Society of Hematology Annual Meeting and Exposition.With a median follow-up of 39.4 months, the analysis presented shows a statistically significant 42% reduction in the risk of death among patients receiving the Blenrep combination  versus the Darzalex arm  .Also Read: GSK’s Withdrawn Multiple Myeloma Drug Shows Encouraging Combination Therapy Data In Second Late-Stage Study. Although the median overall survival  was not reached in either arm of the study, the projected mOS for BVd is 84 months compared to 51 months for the Darzalex combo arm","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/NWjN.DYWzHQX4u4bsFHAOw--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/6b9ce5a8b7bb8eb2d7cad616cf81a0c6","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/NWjN.DYWzHQX4u4bsFHAOw--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/6b9ce5a8b7bb8eb2d7cad616cf81a0c6"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/gsks-blood-cancer-drug-shows-181436592.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1244550221.USD","LU0795875169.SGD","LU1829250122.USD","OS","LU1732799900.SGD","BK4559","LU1267930813.SGD","BK4097","LU1059921491.USD","GSK","IE00B19Z3581.USD","LU1221951046.USD","LU1023059063.AUD","LU1066053197.SGD","LU0345770308.USD","LU0912757837.SGD","BK4550","BK4007","LU0058720904.USD","LU1935042991.SGD","LU1894683348.USD","LU0234570918.USD","LU1914381329.SGD","LU2089984988.USD","BK4581","LU1585245621.USD","GSK.UK","BK4592","IE0002141913.USD","IE00B7SZLL34.SGD","BK4588","IE00BVYPNV92.GBP","IE00BJT1NW94.SGD","IE00BVYPNW00.USD","LU0889566641.SGD","IE00B1BXHZ80.USD","LU2347655156.SGD","LU1732800096.USD","IE00BSNM7G36.USD","JNJ","LU1674673691.USD","LU1221951129.SGD","LU0466842654.USD","IE00BJJMRZ35.SGD","IE00B19Z3B42.SGD","IE00B2B36J28.USD","LU0098860793.USD","IE0034235303.USD","BK4532","LU1894683264.USD"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.onestream.com","stockEarnings":[{"period":"1week","weight":0.0203},{"period":"1month","weight":-0.0275},{"period":"3month","weight":-0.0891},{"period":"6month","weight":0.483},{"period":"ytd","weight":0.483}],"compareEarnings":[{"period":"1week","weight":-0.0216},{"period":"1month","weight":0.0011},{"period":"3month","weight":0.0403},{"period":"6month","weight":0.0857},{"period":"1year","weight":0.2506},{"period":"ytd","weight":0.2437}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"exchange":"NASDAQ","name":"Onestream Inc","nameEN":"Onestream Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Onestream Inc(OS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Onestream Inc(OS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Onestream Inc,OS,Onestream Inc股票,Onestream Inc股票老虎,Onestream Inc股票老虎国际,Onestream Inc行情,Onestream Inc股票行情,Onestream Inc股价,Onestream Inc股市,Onestream Inc股票价格,Onestream Inc股票交易,Onestream Inc股票购买,Onestream Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Onestream Inc(OS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Onestream Inc(OS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction